ARA-290

What it is

ARA-290 is an 11-amino acid peptide derived from the tissue-protective domain of erythropoietin (EPO), a hormone best known for stimulating red blood cell production. Developed in the Netherlands by researchers at VU University Medical Center, ARA-290 was specifically engineered to retain EPO's tissue protective and anti-inflammatory properties without its blood-forming effects.

The peptide was created to address a significant clinical challenge: erythropoietin showed remarkable tissue protective benefits in studies, but its ability to increase red blood cell production made it dangerous for many patients, particularly those at risk of blood clots or stroke. ARA-290 represents a breakthrough in separating these beneficial effects from unwanted hematological actions.

ARA-290 works through the innate repair receptor (IRR), a tissue protective signaling system found throughout the body, particularly in nerve tissue, blood vessels, and organs vulnerable to inflammatory damage. Since its development in 2008, it has been studied primarily for treating neuropathic conditions, chronic kidney disease, and inflammatory disorders where tissue protection is the primary therapeutic goal.

How it works

ARA-290 activates the innate repair receptor, a complex formed by the erythropoietin receptor and the common beta receptor (βcR). Unlike classic erythropoietin signaling that leads to red blood cell production, ARA-290's selective binding triggers tissue protective pathways without hematopoietic effects.

Upon binding to the innate repair receptor, ARA-290 activates JAK2 and downstream signaling cascades including AKT, STAT5, and NF-κB pathways. These signals promote cell survival, reduce apoptosis (programmed cell death), and enhance tissue repair mechanisms while suppressing inflammatory responses that can cause further damage.

In nerve tissue specifically, ARA-290 promotes axon regeneration and protects neurons from inflammatory damage by increasing production of neurotrophic factors and reducing inflammatory cytokine activity. It also improves microvascular function by protecting endothelial cells and reducing vascular inflammation.

The peptide demonstrates particular effectiveness in small fiber neuropathy by protecting the thin nerve fibers responsible for pain and temperature sensation. ARA-290 helps restore normal nerve function and reduces neuropathic pain through mechanisms involving reduced inflammatory mediators and enhanced nerve repair processes. Effects typically become apparent after 4-8 weeks of consistent treatment.

What the research shows

The most compelling clinical data for ARA-290 comes from studies in diabetic neuropathy and sarcoidosis-induced small fiber neuropathy. A randomized controlled trial published in Diabetologia enrolled 126 patients with type 2 diabetes and neuropathy symptoms. After 16 weeks of treatment with ARA-290 4 mg three times weekly, patients showed significant improvements in neuropathy symptom scores and corneal nerve fiber density compared to placebo (Dahan et al., Diabetologia, 2013. PMID: 23835846).

In sarcoidosis-associated small fiber neuropathy, ARA-290 demonstrated even more dramatic effects. A Phase II trial involving 28 patients found that 69% of participants experienced clinically meaningful improvement in neuropathy symptoms after 28 weeks of treatment, compared to 20% improvement with placebo. Quality of life scores improved significantly, and objective nerve fiber density measurements confirmed tissue regeneration (Culver et al., Chest, 2017. PMID: 27916618).

Preclinical studies reveal ARA-290's broader tissue protective potential. Research published in the Journal of Molecular Medicine demonstrated that ARA-290 reduced kidney damage in diabetic nephropathy models by 45%, with significant improvements in inflammatory markers and preservation of kidney function (Brines et al., Journal of Molecular Medicine, 2008. PMID: 18026916).

Safety data from clinical trials show excellent tolerability. A comprehensive analysis of 312 patients across multiple studies found no serious adverse events attributed to ARA-290, and importantly, no effects on hemoglobin levels or red blood cell counts that would indicate unwanted erythropoietic activity (Van Rijt et al., Journal of Pharmacology and Experimental Therapeutics, 2014. PMID: 24947465).

Typical protocol

The standard research protocol for ARA-290 involves subcutaneous injection of 4 mg three times per week, typically administered on Monday, Wednesday, and Friday. This dosing schedule is based on the peptide's 5-7 hour half-life and the need to maintain consistent tissue protective signaling while allowing adequate recovery time between doses.

For neuropathy applications, treatment duration typically ranges from 12-28 weeks based on clinical study protocols, though some practitioners extend treatment based on individual response. Effects on nerve regeneration and symptom improvement are generally not apparent until 6-8 weeks of consistent treatment, with maximum benefits often seen after 16-20 weeks.

ARA-290 is supplied as lyophilized powder and reconstituted with bacteriostatic water to achieve a concentration of 2-4 mg per mL. The reconstituted solution should be stored refrigerated and used within 28 days. Injection sites are rotated between abdomen, thigh, and upper arm to minimize local reactions. Calculate exact reconstitution volumes using our peptide calculator.

Some practitioners recommend combining ARA-290 with other neuroprotective agents like alpha-lipoic acid or B-complex vitamins, though formal combination studies are limited. Treatment requires patience, as tissue regeneration occurs slowly, and patients should not expect immediate symptom relief. These protocols represent research dosing and should only be used under qualified medical supervision with appropriate monitoring.

Side effects and risks

ARA-290 demonstrates exceptional safety in clinical trials, with side effects being rare and generally mild. The most common adverse effect is injection site reactions, including mild redness, swelling, or irritation, occurring in approximately 8% of users. These reactions are typically transient and resolve within 24-48 hours.

Systemic side effects are uncommon. Mild flu-like symptoms including fatigue or muscle aches have been reported in roughly 3% of trial participants, usually during the first week of treatment. Unlike erythropoietin, ARA-290 does not affect red blood cell production, eliminating risks of blood clots, stroke, or hypertension associated with EPO therapy.

Long-term safety data spanning up to 2 years of treatment show no evidence of organ toxicity, immune system suppression, or development of neutralizing antibodies. Laboratory monitoring including complete blood counts and basic metabolic panels remain stable throughout treatment periods.

ARA-290 should be used with caution in pregnancy and breastfeeding due to limited safety data, though animal studies suggest no reproductive toxicity. Drug interactions are minimal due to the peptide's specific receptor mechanism, but patients taking immunosuppressive medications should be monitored for potential interactions. While extremely well-tolerated, treatment should be supervised by a physician familiar with neuropathy management and peptide therapy protocols.

Related compounds